National Cancer Institute Early Career Cancer Clinical Investigator Award

  • Aisner, Joseph (CoPI)
  • BERTINO, JOSEPH ROCCO (CoPI)
  • Delnevo, Cristine (CoPI)
  • DiPaola, Robert S. (CoPI)
  • Foran, David (CoPI)
  • Ganesan, Shridar (CoPI)
  • Haffty, Bruce (CoPI)
  • Heckman, Carolyn J. (CoPI)
  • Javidian, Parisa (CoPI)
  • Kane, Michael (CoPI)
  • Kinney, Anita Y. (CoPI)
  • Lattime, Edmund E.C (CoPI)
  • Libutti, Steven (CoPI)
  • Liu, Chen (CoPI)
  • Lu, Shou-En (CoPI)
  • Manne, Sharon (CoPI)
  • Mehnert, Janice (CoPI)
  • Rabinowitz, Joshua D. (CoPI)
  • Sant'angelo, Derek B. (CoPI)
  • Saunders, Tracie (CoPI)
  • Shen, Zhiyuan (CoPI)
  • Shih, Weichung (CoPI)
  • Tanzer, Linda Loughman (CoPI)
  • White, Eileen P. (CoPI)
  • Zheng, Steven (CoPI)
  • Zong, Wei-Xing (CoPI)
  • Libutti, Steven S.K (PI)
  • Berger, Adam C. (CoPI)
  • Kinney, Anita (CoPI)
  • Heckman, Carolyn (CoPI)
  • Chan, Chang C.S (CoPI)
  • Foran, David D.J (CoPI)
  • Sant'Angelo, Derek (CoPI)
  • Bandera, Elisa (CoPI)
  • Riedlinger, Gregory M. (CoPI)
  • In, Haejin H (CoPI)
  • Liu, Hao H.Y (CoPI)
  • Rabinowitz, Joshua J.D (CoPI)
  • Zheng, Steven S (CoPI)
  • Jabbour, Salma (CoPI)
  • Ganesan, Shridar (CoPI)
  • Zong, Wei-Xing (CoPI)
  • Shen, Zhiyuan Z (CoPI)
  • Notterman, Daniel D.A (CoPI)
  • August, David (CoPI)
  • Laskin, Debra D.L (CoPI)
  • Denicola, Geraldine A. (CoPI)
  • Rubin, Eric (CoPI)
  • Goodin, Susan (CoPI)
  • Gallo, Jose J.M (CoPI)
  • Chin, Khew-voon K (CoPI)
  • Leibowitz, Michael J. (CoPI)
  • Shen, Michael M.M (CoPI)
  • Amenta, Peter S. (CoPI)
  • Cunningham, Regina S. (CoPI)
  • Spaulding, Heidi (CoPI)
  • Ravikumar, T T.S (CoPI)
  • Kinzy, Terri T.G (CoPI)
  • Hait, William N. (CoPI)

Project Details

Description

Project Summary/Abstract Dr. George has ongoing clinical trials that are evaluating novel combinations for the management of breast cancer. This supplement will support the collaborative efforts between clinical investigators and basic scientists to investigate biomarker driven strategies for further investigations. Based on these results, larger multi- institutional studies will be opened within ETCTN and cooperative groups to propel therapeutic advancements in breast cancer. Our goals and objectives align with the goals of the NCI to advance broad spectrum of cancer research to develop effective tolerable therapies for our patients.
StatusActive
Effective start/end date3/1/972/28/25

Funding

  • National Cancer Institute: $299,523.00
  • National Cancer Institute: $3,036,738.00
  • National Cancer Institute: $1,508,494.00
  • National Cancer Institute: $125,000.00
  • National Cancer Institute: $3,025,267.00
  • National Cancer Institute: $200,000.00
  • National Cancer Institute: $3,025,267.00
  • National Cancer Institute: $2,945,906.00
  • National Cancer Institute: $2,945,907.00
  • National Cancer Institute: $124,999.00
  • National Cancer Institute: $3,504,376.00
  • National Cancer Institute: $108,846.00
  • National Cancer Institute: $1,507,000.00
  • National Cancer Institute: $119,250.00
  • National Cancer Institute: $199,788.00
  • National Cancer Institute: $300,000.00
  • National Cancer Institute: $127,296.00
  • National Cancer Institute: $3,028,552.00
  • National Cancer Institute: $2,415,701.00
  • National Cancer Institute: $3,128,377.00
  • National Cancer Institute: $390,587.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.